Key predictors of long-term outcomes in BCMA-targeted CAR-T therapy for relapsed/refractory multiple myeloma
Abstract Background B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy exhibits high response rates in patients with relapsed/refractory multiple myeloma (r/r MM). However, the specific factors that influence the response duration remain poorly understood. Met...
Saved in:
| Main Authors: | Ning An, Juan Li, Pan Luo, Di Wang, Peiling Zhang, Chang Shu, Songbai Cai, Qiuxia Yu, Xinyu Wen, Xinran Wang, Wei Mu, Jianlin Hu, Chunrui Li |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-05-01
|
| Series: | Journal of Translational Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12967-025-06543-x |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
BCMA CAR-T therapy combined with pomalidomide is a safe and effective treatment for relapsed/refractory multiple myeloma
by: Yuhan Yan, et al.
Published: (2024-11-01) -
BCMA CAR-T therapy as salvage therapy in patients with plasmablastic myeloma
by: Chengwei Jin, et al.
Published: (2025-12-01) -
Case Report: BCMA-targeting CAR T-cell therapy induces complete and durable remission in relapsed extramedullary plasmablastic multiple myeloma
by: Lili Zhou, et al.
Published: (2025-05-01) -
Resistance Mechanisms to BCMA Targeting Bispecific Antibodies and CAR T-Cell Therapies in Multiple Myeloma
by: Brandon Tedder, et al.
Published: (2025-07-01) -
BCMA/GPRC5D bispecific CAR T-cell therapy for relapsed/refractory multiple myeloma with extramedullary disease: a single-center, single-arm, phase 1 trial
by: Hao Yao, et al.
Published: (2025-05-01)